Skip to main content
Top
Published in: Rheumatology International 11/2011

01-11-2011 | Case Report

Pentoxifylline for the treatment of anterior uveitis in Behcet’s disease: possible alternative for TNF blockers

Authors: Simone Appenzeller, Elizabeth Hazel

Published in: Rheumatology International | Issue 11/2011

Login to get access

Abstract

Behcet’s disease is an inflammatory disorder of unknown cause, characterized by recurrent oral aphthous ulcers, genital ulcers, uveitis, and skin lesions. All these common manifestations are self-limiting except for the ocular attacks. The objective of the present study is to report the efficacy of pentoxifylline for ocular involvement in Behcet’s disease. We report a patient with ocular involvement secondary to Behcet’s disease which was corticosteroid dependent and refractory to azathioprine treatment. Pentoxifylline was added with amelioration of inflammation. Pentoxifylline may be a useful treatment option in patients with Behcet’s disease, where other immunosuppressives have failed or are contra-indicated.
Literature
1.
go back to reference Kaklamani VG, Vaiopoulos G, Kaklamanis PH (1998) Behçet’s disease. Semin Arthritis Rheum 27:197–217PubMedCrossRef Kaklamani VG, Vaiopoulos G, Kaklamanis PH (1998) Behçet’s disease. Semin Arthritis Rheum 27:197–217PubMedCrossRef
2.
4.
go back to reference Kaklamani VG, Kaklamanis PG (2001) Treatment of Behçet’s disease—an update. Semin Arthritis Rheum 30:299–312PubMedCrossRef Kaklamani VG, Kaklamanis PG (2001) Treatment of Behçet’s disease—an update. Semin Arthritis Rheum 30:299–312PubMedCrossRef
5.
go back to reference Yazici H, Barnes CG (1991) Practical treatment recommendations for pharmacotherapy of Behçet’s syndrome. Drugs 42:796–804PubMedCrossRef Yazici H, Barnes CG (1991) Practical treatment recommendations for pharmacotherapy of Behçet’s syndrome. Drugs 42:796–804PubMedCrossRef
6.
go back to reference Hatemi G, Silman A, Bang D, Bodaghi B, Chamberlain AM, Gul A et al (2009) Management of Behçet disease: a systematic literature review for the European League against rheumatism evidence-based recommendations for the management of Behçet disease. Ann Rheum Dis 68:1528–1534PubMedCrossRef Hatemi G, Silman A, Bang D, Bodaghi B, Chamberlain AM, Gul A et al (2009) Management of Behçet disease: a systematic literature review for the European League against rheumatism evidence-based recommendations for the management of Behçet disease. Ann Rheum Dis 68:1528–1534PubMedCrossRef
7.
go back to reference International Study Group for Behçet’s Disease (1990) Criteria for diagnosis of Behçet’s disease. Lancet 335:1078–1080 International Study Group for Behçet’s Disease (1990) Criteria for diagnosis of Behçet’s disease. Lancet 335:1078–1080
8.
go back to reference Deuter CM, Kötter I, Wallace GR, Murray PI, Stübiger N, Zierhut M (2008) Behçet’s disease: ocular effects and treatment. Prog Retin Eye Res 27:111–136PubMedCrossRef Deuter CM, Kötter I, Wallace GR, Murray PI, Stübiger N, Zierhut M (2008) Behçet’s disease: ocular effects and treatment. Prog Retin Eye Res 27:111–136PubMedCrossRef
9.
go back to reference BenEzra D, Cohen E (1986) Treatment and visual prognosis in Behcet’s disease. Br J Ophthalmol 70:589–592PubMedCrossRef BenEzra D, Cohen E (1986) Treatment and visual prognosis in Behcet’s disease. Br J Ophthalmol 70:589–592PubMedCrossRef
10.
go back to reference Kural-Seyahi E, Fresko I, Seyahi N (2003) The long-term mortality and morbidity of Behcet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore) 82:60–76CrossRef Kural-Seyahi E, Fresko I, Seyahi N (2003) The long-term mortality and morbidity of Behcet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore) 82:60–76CrossRef
12.
go back to reference Matsumura N, Mizushima Y (1975) Leucocyte movement and colchicine treatment in Behcet’s disease. Lancet 2:813PubMedCrossRef Matsumura N, Mizushima Y (1975) Leucocyte movement and colchicine treatment in Behcet’s disease. Lancet 2:813PubMedCrossRef
13.
go back to reference Aktulga E, Altac M, Muftuoglu A, Ozyazgan Y, Pazarli H, Tuzun Y et al (1980) A double blind study of colchicine in Behcet’s disease. Haematologica 65:399–402PubMed Aktulga E, Altac M, Muftuoglu A, Ozyazgan Y, Pazarli H, Tuzun Y et al (1980) A double blind study of colchicine in Behcet’s disease. Haematologica 65:399–402PubMed
14.
go back to reference Thornhill MH, Baccaglini L, Theaker E, Pemberton MN (2007) A randomized, double-blind, placebo-controlled trial of pentoxifylline for the treatment of recurrent aphthous stomatitis. Arch Dermatol 143:463–470PubMedCrossRef Thornhill MH, Baccaglini L, Theaker E, Pemberton MN (2007) A randomized, double-blind, placebo-controlled trial of pentoxifylline for the treatment of recurrent aphthous stomatitis. Arch Dermatol 143:463–470PubMedCrossRef
Metadata
Title
Pentoxifylline for the treatment of anterior uveitis in Behcet’s disease: possible alternative for TNF blockers
Authors
Simone Appenzeller
Elizabeth Hazel
Publication date
01-11-2011
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 11/2011
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-009-1305-9

Other articles of this Issue 11/2011

Rheumatology International 11/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine